<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03596411</url>
  </required_header>
  <id_info>
    <org_study_id>Cohort 2018</org_study_id>
    <nct_id>NCT03596411</nct_id>
  </id_info>
  <brief_title>The Detection of Barrett's Esophagus by Gastrointestinal Endoscopy Prevents Esophageal Carcinoma in Morbid Obese After Sleeve Gastrectomy</brief_title>
  <acronym>Refleeve</acronym>
  <official_title>Refleeve : A Retrospective Study to Evaluate the Prevalence of the Barett's Esophagus by Gastro-osephagal Endoscopy in Morbid Obese Patients Treated by Sleeve Gastrectomy and the Advantage of the Systematic Detection in the Prevention of Esophageal Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nice</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nice</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Severe Gastroesophageal reflux disease (GERD) leading to a chronic aggression of esophagus
      mucosa, called Barrett's esophagus is a main complication of Sleeve gastrectomy for morbid
      obesity. Barrett's esophagus is considered as a early stage of neoplastic transformation to
      adenocarcinoma. Since this last years, six european bariatric centers have adopted the policy
      to realize endoscopy before and five years or more after sleeve gastrectomy. Investigators
      worked out a database comprizing the Endoscopic features and patient characteristics.
      Refleeve projet aim to analyse the long term follow-up datas of 100 patients, evaluate the
      prevalence of Barret's esophagus and investigate the advantage of the systemetic detection to
      prevent esophagus adenocarcinomas.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 17, 2018</start_date>
  <completion_date type="Anticipated">November 17, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 17, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Sleeve gastrectomy</measure>
    <time_frame>5 years</time_frame>
    <description>Gastroesophageal endoscopic features before and five years after sleeve gastrectomy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Obesity related comorbidity</measure>
    <time_frame>5 years</time_frame>
    <description>obesity related comorbidity before and five years or more after sleeve gastrectomy</description>
  </secondary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Gastroesophageal Reflux</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Gastroesophagal reflux disease (GERD) in morbid obese after sleeve gastrectomy
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who had had SG with a minimum follow-up of 5 years, without signs of
             Barrett's esophagus before SG;

          -  An upper GI endoscopy before the SG;

          -  An upper GI endoscopy indicating that no Barrett's esophagus was present at the time
             of the SG;

          -  An upper GI endoscopy done with the scope of searching for the endoscopic anomalies of
             the Barrett's esophagus according to the international guidelines for the diagnosis of
             Barrett's esophagus 9.

          -  Endoscopic biopsies according to the international guidelines for the diagnosis of
             Barrett's esophagus 9.

        Exclusion Criteria:

          -  SG as a conversional procedure from another bariatric procedure such as the gastric
             banding;

          -  No upper GI endoscopy before the SG

          -  Barrett's esophagus before the SG;

          -  A second procedure after the SG such as the conversion to Roux-en-Y gastric bypass or
             duodenal switch;

          -  An upper GI endoscopy done not following the international guidelines for the
             diagnosis of Barrett's esophagus9.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>IANNELLI Antonio, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chirurgie Digestive, CHU de Nice</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>IANNELLI Antonio, PhD</last_name>
    <phone>+33492036376</phone>
    <email>iannelli.a@chu-nice.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU de Nice</name>
      <address>
        <city>Nice</city>
        <state>Alpes Maritimes</state>
        <zip>06001</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>IANNELLLI, PhD</last_name>
      <phone>+33492036376</phone>
      <email>iannelli.a@chu-nice.fr</email>
    </contact>
    <investigator>
      <last_name>Iannelli Antonio, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>May 17, 2018</study_first_submitted>
  <study_first_submitted_qc>July 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 23, 2018</study_first_posted>
  <last_update_submitted>July 20, 2018</last_update_submitted>
  <last_update_submitted_qc>July 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophageal Neoplasms</mesh_term>
    <mesh_term>Gastroesophageal Reflux</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

